Silo Pharma issues 165,000 unregistered shares in asset purchase deal
SILO•Unregistered share issuance tied to asset purchase agreement
- Silo Pharma issued 165,000 common shares in an unregistered sale tied to an asset purchase agreement signed Aug. 18, 2026.
- Stock went to Parkview Consulting as consideration for software, technology, domain names, and related intellectual property.
- Shares carry a lock-up until the earlier of 12 months, a change in control, or company consent.
- The transaction relied on the Securities Act Section 4(a)(2) private placement exemption.
